Iqvia (IQV) Receives New Coverage from Analysts at Mitsubishi UFJ Financial Group
Mitsubishi UFJ Financial Group started coverage on shares of Iqvia (NYSE:IQV) in a report published on Friday morning. The firm issued a neutral rating and a $112.00 price objective on the medical research company’s stock.
IQV has been the topic of a number of other research reports. KeyCorp restated a sector weight rating and set a $100.00 target price on shares of Iqvia in a research note on Friday, November 10th. Zacks Investment Research upgraded shares of Iqvia from a hold rating to a buy rating and set a $107.00 target price on the stock in a research note on Wednesday, October 11th. Credit Suisse Group restated an outperform rating and set a $110.00 target price (up previously from $98.00) on shares of Iqvia in a research note on Monday, October 16th. BidaskClub upgraded shares of Iqvia from a buy rating to a strong-buy rating in a research note on Saturday, August 19th. Finally, Mizuho cut shares of Iqvia from a buy rating to a neutral rating and set a $90.00 target price on the stock. in a research note on Thursday, November 9th. Ten equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Iqvia has an average rating of Buy and a consensus price target of $105.61.
Shares of Iqvia (NYSE:IQV) traded up $0.59 during trading on Friday, hitting $102.06. 2,334,663 shares of the stock traded hands, compared to its average volume of 1,356,440. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia has a 1-year low of $74.73 and a 1-year high of $110.67. The stock has a market cap of $21,104.53, a PE ratio of 23.17, a PEG ratio of 1.62 and a beta of 0.61.
In other news, insider Ari Bousbib sold 46,080 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $94.91, for a total value of $4,373,452.80. Following the sale, the insider now directly owns 1,036,839 shares in the company, valued at approximately $98,406,389.49. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James H. Erlinger III sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $94.52, for a total transaction of $945,200.00. Following the completion of the sale, the insider now owns 27,340 shares in the company, valued at $2,584,176.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,631,093 shares of company stock worth $1,640,970,687. Corporate insiders own 6.40% of the company’s stock.
WARNING: “Iqvia (IQV) Receives New Coverage from Analysts at Mitsubishi UFJ Financial Group” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/16/iqvia-iqv-receives-new-coverage-from-analysts-at-mitsubishi-ufj-financial-group.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Stock Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related stocks with our FREE daily email newsletter.